Apparatus and method for controlling placement of intraocular implants

Information

  • Patent Grant
  • 11116625
  • Patent Number
    11,116,625
  • Date Filed
    Friday, September 28, 2018
    5 years ago
  • Date Issued
    Tuesday, September 14, 2021
    3 years ago
Abstract
Some embodiments disclosed herein relate to devices and methods for controlling placement of intraocular implants within a patient's eye including but not limited to placement within or near the collector ducts of Schlemm's canal located behind the trabecular meshwork. In some embodiments, a handheld peristaltic rotor device having a compression element can be positioned on a corneal surface of the eye and rotated to create a peristaltic movement of blood in one or more episcleral veins to generate blood reflux within Schlemm's canal such that one or more collector ducts, or channels, of Schlemm's canal can be located. In some embodiments, an implant can be implanted near the identified location of the one or more collector ducts, or channels.
Description
FIELD OF THE INVENTION

This disclosure generally relates to intraocular implants and the placement thereof within the eye, and relates more particularly to an apparatus and method for identifying locations of collector ducts, or channels, of the eye and positioning intraocular implants near the identified locations.


BACKGROUND

A human eye is a specialized sensory organ capable of light reception and is able to receive visual images. Aqueous humor is a transparent liquid that fills at least the region between the cornea, at the front of the eye, and the lens. A trabecular meshwork, located in an anterior chamber angle, which is formed between the iris and the cornea, normally serves as a drainage channel for aqueous humor from the anterior chamber so as to maintain a balanced pressure within the anterior chamber of the eye.


About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentations, etiologies, and treatment modalities. Glaucoma causes pathological changes in the optic nerve, visible on the optic disk, and it causes corresponding visual field loss, resulting in blindness if untreated. Lowering intraocular pressure is the major treatment goal in all glaucomas.


In glaucomas associated with an elevation in eye pressure (intraocular hypertension), the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork normally allows the aqueous humor to enter Schlemm's canal, which then empties into aqueous collector channels in the posterior wall of Schlemm's canal and then into aqueous veins, which form the episcleral venous system. Aqueous is continuously secreted by a ciliary body around the lens, so there is a constant flow of aqueous from the ciliary body to the anterior chamber of the eye. Pressure within the eye is determined by a balance between the production of aqueous and its exit through the trabecular meshwork (major route) and uveoscleral outflow (minor route). The portion of the trabecular meshwork adjacent to Schlemm's canal (the juxtacanilicular meshwork) causes most of the resistance to aqueous outflow.


Glaucoma is broadly classified into two categories: closed-angle glaucoma, also known as angle closure glaucoma, and open-angle glaucoma. Closed-angle glaucoma is caused by closure of the anterior chamber angle by contact between the iris and the inner surface of the trabecular meshwork. Closure of this anatomical angle prevents normal drainage of aqueous from the anterior chamber of the eye. Open-angle glaucoma is any glaucoma in which the exit of aqueous through the trabecular meshwork is diminished while the angle of the anterior chamber remains open. For most cases of open-angle glaucoma, the exact cause of diminished filtration is unknown. Primary open-angle glaucoma is the most common of the glaucomas, and is often asymptomatic in the early to moderately advanced stages of glaucoma. Patients may suffer substantial, irreversible vision loss prior to diagnosis and treatment. However, there are secondary open-angle glaucomas that may include edema or swelling of the trabecular spaces (e.g., from corticosteroid use), abnormal pigment dispersion, or diseases such as hyperthyroidism that produce vascular congestion.


Because the trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous, they are logical targets for surgical removal in the treatment of open-angle glaucoma. In addition, minimal amounts of tissue need be altered and existing physiologic outflow pathways can be utilized. Some procedures bypass the trabecular meshwork and juxtacanilicular tissue to drain fluid to physiologic outflow channels.


SUMMARY

In accordance with some embodiments, a method of positioning intraocular implants at or near collector ducts of Schlemm's canal. The method comprises positioning a handheld peristaltic rotor device on a corneal surface of an eye, the handheld peristaltic rotor device comprising a rotor having a plurality of compression elements; rotating the rotor such that the plurality of compression elements create a peristaltic movement of blood from one or more occluded episcleral veins to Schlemm's canal; identifying a location of at least one collector duct, or channel, of the eye based on the refluxed blood within Schlemm's canal; delivering an implant through an incision (e.g., corneal incision or incision through a limbus) in the eye; and placing an implant within the eye such that the implant is located at or near the identified location of the at least one collector duct. The implant may drain aqueous from an anterior chamber of the eye to Schlemm's canal and bypass the trabecular meshwork.


In accordance with some embodiments, a method of identifying a location of one or more collector ducts of Schlemm's canal of an eye is disclosed. The method comprises positioning a handheld peristaltic rotor device on a surface of an eye, the handheld rotor device comprising a rotor having a compression element; rotating the rotor such that the compression element of the rotor induces a peristaltic movement of blood into Schlemm's canal from one or more occluded episcleral veins, and identifying a location of at least one collector duct of the eye based at least in part on the refluxed blood. In some embodiments, rotating the rotor comprises manual rotation (partial revolution rotation or multiple turn or revelation rotation). The rotation may be effected by a handle or level coupled to the rotor or by directly rotating the rotor with the fingers. In some embodiments, rotating the rotor comprises winding an internal spring by manually rotating the rotor in a first (e.g., clockwise) direction and then releasing the rotor to cause the spring to unwind and the rotor to rotate in an opposite (e.g., counter-clockwise) direction.


A handheld peristaltic rotor device for locating collector ducts of Schlemm's canal of an eye is also disclosed. The handheld peristaltic rotor device comprises a rotor having a proximal portion and a distal open end, the distal open end comprising a distal rim surface and a corneal clearance portion; and a plurality of compression elements protruding from the distal rim surface, wherein the rotor and the plurality of compression elements are configured to cause a blood reflux into Schlemm's canal from one or more occluded episcleral surface region of an eye by positioning the rotor on the episcleral surface of the eye and rotating the rotor. The handheld peristaltic rotor device may also comprise an optical element that remains stationary while the rotor is rotated either by hand or a wound spring. The device may comprise a handle connected to the proximal portion of the rotor to facilitate manual rotation of the rotor. In some embodiments, a spring is included having a first end coupled to the optical portion and a second end coupled to the proximal portion of the rotor, wherein the spring is configured to cause rotation of the rotor. The plurality of compression elements may comprise ribs or fins that taper in height along their length so as to induce the peristaltic effect. The lengths of the compression elements may overlap. The plurality of compression elements may be formed of a compliant polymeric material so as to deform when in contact with an eye surface. The optical element or portion may include a magnifying lens (e.g., gonio lens) to facilitate visualization of reflux. The optical element or portion may be detachably coupled to the proximal portion of the rotor fi the rotor is intended for single use or for sterilization.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a sectional view of an overall anatomy of an eye.



FIG. 2 is a close-up sectional view of an anterior chamber angle of the eye of FIG. 1.



FIG. 3A illustrates a diagram of normal aqueous fluid outflow.



FIG. 3B illustrates a diagram of blood reflux into Schlemm's canal caused by occlusion of at least one episcleral vein.



FIGS. 4A-4B illustrate an embodiment of a handheld peristaltic rotor device for generating blood reflux into Schlemm's canal.



FIGS. 4C-4D illustrate an embodiment of a handheld peristaltic rotor device having an undercut.



FIGS. 4E-4I illustrate a top perspective view, a side view, a bottom perspective view, a bottom view and a side cross-section view, respectively, of an embodiment of a handheld peristaltic rotor device.



FIG. 5 illustrates a diagram illustrating blood reflux within Schlemm's canal generated by the devices of FIGS. 4A-4I.



FIG. 6A illustrates an embodiment of a method for delivering implants at or near a collector duct, or channel, identified by the blood reflux produced in Schlemm's canal.



FIG. 6B illustrates the method of FIG. 6A using a peristaltic rotor device.



FIG. 7 illustrates placement of an implant at or near a location (e.g., an identified location based on blood reflux) of a collector duct, or channel, of Schlemm's canal of the eye.





DETAILED DESCRIPTION

Embodiments of the invention will now be described with reference to the accompanying figures, wherein like numerals refer to like elements throughout. The terminology used in the description presented herein is not intended to be interpreted in any limited or restrictive manner, simply because it is being utilized in conjunction with a detailed description of certain specific embodiments of the invention. Furthermore, embodiments of the invention may comprise several novel features, no single one of which is solely responsible for its desirable attributes or which is essential to practicing the inventions herein described.


In some circumstances, an intraocular implant (e.g., a shunt, stent or the like) can be implanted into the trabecular meshwork of the eye of a patient suffering from an ocular disorder, such as glaucoma, so as to create a fluid passageway between the anterior chamber and Schlemm's canal behind the trabecular meshwork in the patient's eye. The fluid passageway allows aqueous fluid to flow from the anterior chamber of the eye through the fluid passageway (e.g., bypass) created by the implant, into Schlemm's canal, and out of the patient's eye through the episcleral venous pathways, thereby relieving the elevated intraocular pressure associated with glaucoma. In some embodiments, the devices and methods described herein can used to facilitate reduction of intraocular pressure in pigmentary glaucoma patients and/or pseudoexfoliation glaucoma patients.


Pressure within the eye is determined by a balance between the production of aqueous fluid and its exit through the canalicular outflow (e.g., through the trabecular meshwork) and uveoscleral outflow routes or pathways. The portion of the trabecular meshwork adjacent to Schlemm's canal (the juxtacanilicular meshwork) is believed to cause most of the resistance to aqueous fluid outflow. Accordingly, it can be advantageous to insert ocular implants, such as shunts or stents, to promote and maintain an increased level of aqueous fluid flow out of Schlemm's canal through the trabecular meshwork.


Schlemm's canal contains numerous outflow channels known as collector ducts, or collector channels. In some circumstances, it can be desirable to place an implant at a position in the trabecular meshwork that is near (e.g., within 1 mm of) one of the collector ducts, or channels, so as to provide an effective fluid passageway between the anterior chamber and Schlemm's canal. The various collector ducts of Schlemm's canal can vary in size, and it can be desirable to position an outlet of the implant near (e.g., within 1 mm of) a large collector duct so as to allow a sufficient amount of fluid to drain out of the anterior chamber of the eye to relieve the elevated intraocular pressure in a more efficient manner.


The implant can be implanted into the trabecular meshwork using a surgical procedure in which the implant is placed in or on a delivery device and inserted through an incision, including a self-sealing incision, in the cornea, limbus, or the adjacent scleral or conjunctival tissue, then transported across the anterior chamber (e.g., in an ab interno manner), and implanted into the trabecular meshwork on the side of the eye substantially across from the incision. In other embodiments, the implant can be implanted on the same side of the eye as the incision (e.g., corneal incision). In some embodiments, the surgical procedure is performed using a surgical microscope positioned over the patient's eye and a gonioprism is used to allow the ophthalmologist or other clinician to see into the anterior chamber of the eye as the implant is implanted. Although the trabecular meshwork can be viewed using this system, the locations of collector ducts of Schlemm's canal are not readily visible because they are hidden behind the trabecular meshwork. Therefore, the ophthalmologist or other clinician may be unable to target a specific collector duct, or channel, when placing the implant. Placement of the implants is sometimes guided by rules of thumb or general guidelines such as placing the implant in the nasal inferior quadrant of the trabecular meshwork, where the collector ducts are believed to be more prevalent. However, because the ophthalmologist may be unable to identify the actual locations of the collector ducts in the eye, the successful placement of the implant near a collector duct, including large collector ducts, can ultimately rely on a degree of chance without use of embodiments of the inventions described herein.


Anatomy



FIG. 1 shows a sectional view of an eye 10, while FIG. 2 shows a close-up view, showing the relative anatomical locations of the trabecular meshwork, the anterior chamber, and Schlemm's canal within the eye 10. Thick collagenous tissue known as the sclera 11 covers the entire eye 10 except that portion covered by the cornea 12. The cornea 12 is a thin transparent tissue that focuses and transmits light into the eye and the pupil 14 which is the circular hole in the center of the iris 13 (colored portion of the eye). The cornea 12 merges into the sclera 11 at a juncture referred to as the limbus 15. The ciliary body 16 begins internally in the eye and extends along the interior of the sclera 11 and becomes the choroid 17. The choroid 17 is a vascular layer of the eye underlying retina 18. The optic nerve 19 transmits visual information to the brain and is sequentially destroyed by glaucoma.


The anterior chamber 20 of the eye 10, which is bound anteriorly by the cornea 12 and posteriorly by the iris 13 and the lens 26, is filled with aqueous fluid. Aqueous humor (also referred to as “aqueous”) is produced primarily by the ciliary body 16 and reaches the anterior chamber angle 25 formed between the iris 13 and the cornea 12 through the pupil 14. In a normal eye, the aqueous is removed through the trabecular meshwork 21. The aqueous passes through the trabecular meshwork 21 into Schlemm's canal 22 and through collector ducts or channels 27, which merge with blood-carrying episcleral veins and into venous circulation. Intraocular pressure of the eye 10 is maintained by the intricate balance of secretion and outflow of the aqueous in the manner described above. Glaucoma is characterized by the excessive buildup of aqueous fluid in the anterior chamber 20 which produces an increase in intraocular pressure (fluids are relatively incompressible and pressure is directed equally to all areas of the eye).


Blood Reflux


With reference to FIG. 3A, aqueous normally flows from the anterior chamber 20 through the fenestrated trabecular meshwork 21 and into Schlemm's canal 22. The aqueous then empties into the aqueous collector ducts, or channels 27 in the posterior wall of Schlemm's canal 22 and then into the blood-carrying episcleral veins 23, which form the episcleral venous system. The aqueous fluid mixes with, and dilutes, the blood in the episcleral veins. The dotted areas indicate blood 28. Aqueous is continuously secreted by a ciliary body around the lens 26, so there is a constant flow of the aqueous from the ciliary body to the anterior chamber 20 of the eye 10. Accordingly, in normal eyes, there is normally minimal to no blood flow within Schlemm's canal 22, as illustrated by the absence of blood (as evidenced by a concentration of red blood cells sufficiently high to be visible to a clinician) within Schlemm's canal 22 in FIG. 3A, thereby making it difficult to observe Schlemm's canal.


With reference to FIG. 3B, blood 28 can be refluxed into Schlemm's canal 22 by occlusion of one or more episcleral veins 23 of the episcleral venous system. For example, if episcleral vein 23B is occluded, the blood pressure rises upstream from the occlusion 29 until blood 28 refluxes into the collector duct 27B and eventually into Schlemm's canal 22. Because of the circumferential flow within Schlemm's canal 22, the blood follows a path of least resistance along Schlemm's canal 22 to another collector duct 27A, 27C, whose episcleral vein is not occluded. As the blood flows within Schlemm's canal 22, the blood is diluted by the aqueous within Schlemm's canal 22. Accordingly, the highest concentration of blood and blood particles within Schlemm's canal 22 is located at or near the inlet to the collector duct 27B. The region of Schlemm's canal adjacent the inlet to the collector duct 27B upstream of the occluded vein 23B, can take on a pinkish color due to the increased concentration of blood (made visible by red blood cells) 28 within the region. The location of the collector duct 27B can thus be identified by observing the pinkish region through a gonioscope. The identified location can then be used to more precisely place an implant near a collector duct, or channel, 27 of Schlemm's canal 22, thereby increasing aqueous outflow and reducing intraocular pressure.


Peristaltic Rotor



FIGS. 4A-4I illustrate various embodiments of a blood reflux generation and/or identification device 30. The blood reflux generation and/or identification device 30 may comprise a handheld peristaltic rotor device for generating blood reflux within Schlemm's canal 22 positioned on a corneal surface of the eye. The handheld peristaltic rotor device 30 can include a handle 38 attached to a rotor member or portion 32. The handle 38 can be an elongated rod made of a substantially rigid material, such as, for example, a polyvinyl chloride (PVC) rod. The handle 38 may be coupled to the rotor member 32 at any suitable location and can extend outward from the rotor member 32 to facilitate rotation of the rotor member 32. The rotor member 32 can be generally cup-shaped, having a distal open end and a proximal end. The distal open end can include a distal rim surface 39 and a corneal clearance portion 36. The proximal end of the rotor member 32 can be connected to the handle 38. The rotor member 32 can include a plurality of anti-suction vents 33 allowing passage of air from the corneal clearance portion 36 to an external surface of the rotor member 32. In some embodiments, the anti-suction vents 33 can be oval-shaped holes circumferentially spaced from the center of the rotor member 32, as best shown in FIGS. 4A and 4B. The holes may have other shapes in other embodiments (e.g., circle, ellipse, oblong shape).


The height of the cup-shaped rotor member 32 can be between about 7 mm to about 20 mm (e.g., 7 mm-10 mm, 10 mm-15 mm, 15 mm-20 mm, 7 mm-15 mm, 10 mm-20 mm, overlapping ranges thereof, or any value within the recited ranges). The diameter of the rotor member 32 can be between about 10 mm to about 25 mm (e.g., 10 mm-20 mm, 10 mm-15 mm, 15 mm-25 mm, 15 mm-20 mm, overlapping ranges thereof, or any value within the recited ranges). Heights and diameters outside these ranges are also possible. The distal rim surface 39 of the rotor member 32 can have an O-ring or a toroidal shape surrounding the corneal clearance portion 36. The distal rim surface 39 of the rotor member 32 can be configured to substantially conform to the contour of the episcleral surface region of the eye. The distal rim surface 39 can have a thickness configured to allow the rotor member 32 to concentrically rotate about the cornea 12. For example, the distal rim surface 39 can have a thickness of about 0.5 mm to about 10 mm (e.g., 0.5 mm-5 mm, 1 mm-5 mm, 0.5 mm-1.5 mm, 0.5 mm to 2 mm, 5 mm to 10 mm, overlapping ranges thereof, or any value within the recited ranges). A fluid or a gel can optionally be applied to the distal rim surface 39 of the rotor member 32.


The corneal clearance portion 36 can have a generally spherical-cap shape or other shape that can conform to the shape of the cornea 12 of an average human eye (e.g., adult or child eye). The height and the diameter of the corneal clearance portion 36 are similar to, or greater than, the height and the diameter size of the cornea 12. The height and the diameter of the corneal clearance portion 36 can allow the distal rim surface 39 of the peristaltic rotor device 30 to rotate about the cornea, without any part of the peristaltic rotor device 30 contacting the cornea. For example, the corneal clearance portion 36 can have a diameter of between about 9 mm and 12 mm. The height of the corneal clearance portion 36 can be between about 0.5 mm to about 3 mm (e.g., between 0.5 and 1.5 mm, between 0.5 mm and 2 mm, between 1 mm and 3 mm, overlapping ranges thereof, or any value within the recited ranges). Diameters and heights outside these ranges are also possible.


The structure of the rotor member 32 can also include an undercut 45, as shown in FIGS. 4C and 4D. The undercut can be used, for example, to increase the accessibility and introduction of devices to the eye, including the cornea, the limbus, or the adjacent scleral or conjunctival tissue of the eye. The undercut 45 can be configured to allow introduction of an elongate tip or a cannula portion 55 of an implant delivery instrument or other surgical instrument, as described in further detail below.


In some embodiments, the rotor member 32 can include two or more undercuts 45 radially spaced apart from each other. In such embodiments, a clinician may use the rotor 32 having two or more undercuts 45 to place a second implant within the eye such that the second implant is located at or near the identified location of a second collector duct. The rotor 32 having two or more undercuts 45 can also be used to determine a desired degree of rotation of the rotor member 32 about the cornea.


All or part of the rotor member 32 can be made of a substantially transparent material (e.g, glass, plastic, silicone, or other materials) so that light reflected from the subject's eye can be received by the distal rim surface 39, propagate through the transparent material, and be emitted by the proximal surface. In some embodiments, the handheld peristaltic rotor device 30 can include a plurality of optical elements configured to refract light reflected by the patient's ocular structure. In some embodiments, an opaque material, such as an opaque plastic can be used for the rotor member 32.


In some embodiments, the rotor member 32 can be formed of a flexible material (e.g., a soft polymer such as silicone) so as to enhance the conformability of the rotor member 32 with the surface of the eye. In other embodiments, the rotor member 32 can be constructed of a rigid or semi-rigid material. In some embodiments, the handle 38 can be made of a rigid or semi-rigid material. In other embodiments, the handle 38 can be made of a flexible material.


With reference to FIGS. 4E-4I, some embodiments of a blood reflux generation device (e.g., handheld peristaltic rotor device) 30 may not include the handle 38. The elements labeled with like numbers as FIGS. 4A-4D may include the same structural and functional features described above. The illustrated embodiment of the device 30 shown in FIGS. 4E-4I shows that the device 30 may include an optical element or portion 40 that can be coupled (permanently or removably) to the rotor member or portion 32. For example, the optical element or portion 40 may be coupled to the rotor member 32 with set screws or other fixation members (not shown) to couple the optical element 40 and the rotor member 32. The set screws or other fixation members may be positioned at various (e.g., 2, 3, 4) spaced-apart locations around a circumference of the optical element 40. The rotor member 32 may be configured for one-time use and be disposable. Accordingly, it may be advantageous to have the optical element or portion 40 be detachable from the rotor member 32 so that that the rotor member or portion 32 can be discarded and the optical element or portion 40 can be re-used. In some embodiments, the rotor member or portion 32 and/or the optical element or portion 40 can be sterilized and re-used. In some embodiments, the entire device 30 may be disposable.


The upper (top) optical element or portion 40 may be configured to remain stationary while the lower (bottom) rotor member or portion 32 is rotated. The optical element or portion 40 includes a goniolens, gonioscope, or gonioprism or other lens or visualization member 42 that advantageously facilitates visualization (e.g., magnified visualization) of the regions of blood 28 where the rotor member 32 has generated blood reflux. The optical element or portion 40 can be held in the hand and does not rotate. The rotor member 32 may be rotated by hand (e.g., using a handle or lever, not shown) or with an internally wound spring 35 (as shown in FIG. 4I).


Compression Elements


The handheld peristaltic rotor device 30 can include a plurality of compression elements 37. In general, the plurality of compression elements 37 can be configured to apply pressure to an episcleral region of the eye, thereby occluding one or more episcleral veins to produce blood reflux within Schlemm's canal 22. The plurality of compression elements 37 can include two or more concentric spiral protrusions on a distal rim surface 39 of the rotor member 32, as best shown in FIGS. 4B, 4D, and 6B. The compression elements 37 may comprise ribs or fins.


The embodiments of the rotor members 32 shown in FIGS. 4E-4I show alternative embodiments of shapes and configurations of the compression elements 37. The compression elements 37 may include a plurality of compliant compression ribs or fins that are configured to spin below the limbus region of the eye to peristaltically force blood into Schlemm's canal. The number and size of the ribs may vary (e.g., 6 ribs, 7 ribs, 8 ribs, 9 ribs, 10 ribs, 11 ribs, 12 ribs).


The plurality of compression elements 37 can be a plurality of linear protrusions having a curved surface, each protrusion having a thickness and a maximum height configured to substantially occlude one or more episcleral veins and produce blood reflux within Schlemm's canal 22. For example, the thickness and the height of a compression element can be about 0.4 mm to about 7 mm (e.g., between 0.4 mm and 1.5 mm, between 0.5 mm and 2.5 mm, between 1 mm and 4 mm, between 2 mm and 6 mm, between 3 mm and 7 mm, overlapping ranges thereof, or any value within the recited ranges). The plurality of compression elements 37 can be formed of any suitable biocompatible material. In some embodiments, the plurality of compression elements 37 can be protrusions having a flat surface or a ridged surface instead of having a curved surface. In some embodiments, the plurality of compression elements 37 can be a ring-shaped protrusion, the ring shape located concentrically with the distal rim surface 39 of the rotor member 32. In another embodiment, the plurality of compression elements 37 can be a plurality of spoke-shaped protrusions extending outward from the center of the rotor member 32. The lower (e.g., contact) surface of the compression elements 37 may be tapered such that a height of the compression element 37 varies from one end to the other (as shown, for example, in FIGS. 4E-4I). The taper profile and positioning of the compression elements 37 may be configured such that there is a continuous overlap of contact between the compression elements 37 and the eye tissue as the rotor member 32 is rotated so as to induce the peristaltic action. After a maximum height portion of a first compression element compresses an episcleral vein, the height tapers to allow the vessel to refill with blood (as compression is reduced due to the tapered profile as rotation continues). Then the maximum height portion of the next successive compression element (due to continued rotation) compresses the episcleral vein again to cause the refilled blood in the episcleral vein to be expelled into Schlemm's canal. This peristaltic mechanism continually repeats as the rotor member 32 is rotated.


In some embodiments, a user (e.g., ophthalmologist or other clinician) can place the rotor member 32 on the episcleral surface of the eye, and then manually rotate the rotor member 32 (e.g., using a handle or lever). The user may rotate the rotor member 32 to a degree that can cause the plurality of compression elements 37 to create a peristaltic movement of blood within episcleral veins, thereby inducing blood reflux within Schlemm's canal 22. In some embodiments, a user may tilt, press, or squeeze the rotor 32 and/or the handle 38 to cause the movement of blood. In some embodiments, the rotor member 32 is rotated (manually or by an internal wound spring) multiple turns or a partial turn (e.g., ¼ turn, ½ turn, ¾ turn). In some embodiments, the rotor member 32 may be rotated automatically with an internally wound spring 35 (as shown, for example, in FIG. 4I). The spring 35 may be positioned within a channel between a portion of the optical element or portion 40 and a component of the rotor member 32. One end of the spring 35 may be coupled to a rotatable component of the rotor member 32 and the other end of the spring may be coupled to the optical element or portion 40. For example, the device 30 can be provided with the spring 35 in an unwound configuration. The clinician can then rotate the rotor member 32 (e.g., in a clockwise manner) to wind up the spring 35 (either before or after placement on the eye) and then release the rotor member 32 to cause the rotor member 32 to rotate (e.g., in a counter-clockwise manner) while the optical element or portion 40 remains stationary. In some embodiments, a high-viscosity lubricant is applied between the components to act as a dampening mechanism to cause the spring 35 to unwind more slowly to facilitate the peristaltic action to generate blood reflux.


Delivery Instrument


In some embodiments, the delivery instrument can be sufficiently long to advance the implant transocularly from the insertion site across the anterior chamber to the implantation site. At least a portion of the instrument can be flexible. Alternatively, the instrument can be rigid. The delivery instrument can comprise a plurality of members longitudinally moveable relative to each other. In some embodiments, at least a portion of the delivery instrument is curved or angled. In some embodiments, a portion of the delivery instrument is rigid and another portion of the instrument is flexible.


In some embodiments, the delivery instrument has a distal curvature. The distal curvature of the delivery instrument may be characterized as a radius of approximately 10 to 30 mm, and preferably about 20 mm.


In some embodiments, the delivery instrument has a distal angle. The distal angle may be characterized as approximately 90 to 170 degrees relative to an axis of the proximal segment of the delivery instrument, and preferably about 145 degrees. The angle can incorporate a small radius of curvature at the “elbow” so as to make a smooth transition from the proximal segment of the delivery instrument to the distal segment. The length of the distal segment may be approximately 0.5 to 7 mm, and preferably about 2 to 3 mm.


In some embodiments, the instruments have a sharpened forward end and are self-trephinating, e.g., self-penetrating, so as to pass through tissue without preforming an incision, hole or aperture. Alternatively, a trocar, scalpel, or similar instrument can be used to pre-form an incision in the eye tissue before passing the implant into such tissue.


For delivery of some embodiments of the ocular implant, the instrument can have a sufficiently small cross section such that the insertion site self seals without suturing upon withdrawal of the instrument from the eye. An outer diameter of the delivery instrument preferably is no greater than about 18 gauge and is not smaller than about 27 gauge.


For delivery of some embodiments of the ocular implant, the incision in the corneal tissue is preferable made with a hollow needle through which the implant is passed. The needle has a small diameter size (e.g., 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 gauge) so that the incision is self sealing and the implantation occurs in a closed chamber with or without viscoelastic. A self-sealing incision also can be formed using a conventional “tunneling” procedure in which a spatula-shaped scalpel is used to create a generally inverted V-shaped incision through the cornea. In a preferred mode, the instrument used to form the incision through the cornea remains in place (that is, extends through the corneal incision) during the procedure and is not removed until after implantation. Such incision-forming instrument either can be used to carry the ocular implant or can cooperate with a delivery instrument to allow implantation through the same incision without withdrawing the incision-forming instrument. Of course, in other modes, various surgical instruments can be passed through one or more corneal incisions multiple times.


Once into the anterior chamber, a delivery instrument can be advanced from the insertion site transocularly into the anterior chamber angle and positioned at a location near the scleral spur. Using the scleral spur as a reference point, the delivery instrument can be advanced further in a generally posterior direction to drive the implant into eye tissue at a location just inward of the scleral spur toward the iris. The placement and implantation of the implant can be performed using a gonioscope or other conventional imaging equipment. The delivery instrument preferably is used to force the implant into a desired position by application of a continual implantation force, by tapping the implant into place using a distal portion of the delivery instrument, or by a combination of these methods. Once the implant is in the desired position, it may be further seated by tapping using a distal portion of the delivery instrument.


The delivery instrument can include an open distal end with a lumen extending therethrough. Positioned within the lumen is preferably a pusher tube that is axially movable within the lumen. The pusher tube can be any device suitable for pushing or manipulating the implant in relation to the delivery instrument, such as, for example, but without limitation a screw, a rod, a stored energy device such as a spring. A wall of the delivery instrument preferably extends beyond pusher tube to accommodate placement within the lumen of a implant. The implant can be secured in position. For example, the implant can be secured by viscoelastic or mechanical interlock with the pusher tube or wall. When the implant is brought into position adjacent the tissue in the anterior chamber angle, the pusher tube is advanced axially toward the open distal end of the delivery instrument. As the pusher tube is advanced, the implant is also advanced. When the implant is advanced through the tissue and such that it is no longer in the lumen of the delivery instrument, the delivery instrument is retracted, leaving the implant in the eye tissue.


Some embodiments can include a spring-loaded or stored-energy pusher system. The spring-loaded pusher preferably includes a button operably connected to a hinged rod device. The rod of the hinged rod device engages a depression in the surface of the pusher, keeping the spring of the pusher in a compressed conformation. When the user pushes the button, the rod is disengaged from the depression, thereby allowing the spring to decompress, thereby advancing the pusher forward.


In some embodiments, an over-the wire system is used to deliver the implant. The implant can be delivered over a wire. Preferably, the wire is self-trephinating. The wire can function as a trocar. The wire can be superelastic, flexible, or relatively inflexible with respect to the implant. The wire can be pre-formed to have a certain shape. The wire can be curved. The wire can have shape memory, or be elastic. In some embodiments, the wire is a pull wire. The wire can be a steerable catheter.


In some embodiments, the wire is positioned within a lumen in the implant. The wire can be axially movable within the lumen. The lumen may or may not include valves or other flow regulatory devices.


In some embodiments, the delivery instrument comprises is a trocar. The trocar may be angled or curved. The trocar can be rigid, semi-rigid or flexible. In embodiments where the trocar is stiff, the implant can be, but need not be relatively flexible. The diameter of the trocar can be about 0.001 inches to about 0.01 inches. In some embodiments, the diameter of the trocar is 0.001, 0.002, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, or 0.01 inches.


In some embodiments, delivery of the implant is achieved by applying a driving force at or near the distal end of the implant. The driving force can be a pulling or a pushing applied generally to the end of the implant.


The instrument can include a seal to prevent aqueous humor from passing through the delivery instrument and/or between the members of the instrument when the instrument is in the eye. The seal can also aid in preventing backflow of aqueous humor through the instrument and out the eye. Suitable seals for inhibiting leakage include, for example, an O-ring, a coating, a hydrophilic agent, a hydrophobic agent, and combinations thereof. The coating can be, for example, a silicone coat such as MDX™ silicone fluid. In some embodiments, the instrument is coated with the coating and a hydrophilic or hydrophobic agent. In some embodiments, one region of the instrument is coated with the coating plus the hydrophilic agent, and another region of the instrument is coated with the coating plus the hydrophobic agent. The delivery instrument can additionally comprise a seal between various members comprising the instrument. The seal can comprise a hydrophobic or hydrophilic coating between slip-fit surfaces of the members of the instrument. The seal can be disposed proximate of the drainage implant when carried by the delivery instrument. Preferably, the seal is present on at least a section of each of two devices that are machined to fit closely with one another.


In some embodiments, the delivery instrument can include a distal end having a beveled shape. The delivery instrument can include a distal end having a spatula shape. The beveled or spatula shape can have a sharpened edge. The beveled or spatula shape can include a recess to contain the implant. The recess can include a pusher or other suitable means to push out or eject the implant.


The delivery instrument further can be configured to deliver multiple implants. In some embodiments, when multiple implants are delivered, the implants can be arranged in tandem.


Method of Use


Visualization



FIG. 5 illustrates a schematic representation of a method of operation of the blood reflux-producing peristaltic rotor device 30. The rotor member 32 can be rotated (manually or by releasing an internal wound spring 35) to cause peristaltic movement of the blood to reflux into Schlemm's canal 22 (as described above). The plurality of compression elements 37 applies sufficient pressure so as to occlude the episcleral veins 23A, 23B. The location of the collector ducts 27A, 27B can be identified (e.g., using the goniolens 42) by the presence of a pinkish region 31 caused by the elevated concentration of blood within the aqueous proximal the inlets of the collector ducts 27A, 27B as compared to the remainder of the sclera. The identified locations of the collector ducts 27A, 27B can then be used to deliver one or more implants within or near the collector ducts 27A, 27B so as to enhance aqueous fluid drainage and thereby reduce intraocular pressure. The identified locations may help show the location of an outflow pathway, including the greatest outflow pathway, to which the surgeon can place the implant to maximize outflow. The identified locations of the collector ducts 27A, 27B can also be used to visualize the efficacy of the implant placed within or near the collector ducts 27A, 27B or for the retrospective placement investigation of the implant. The blood reflux-producing peristaltic rotor device 30 can be used to purge outflow pathways of obstruction.


In some embodiments, a therapeutic agent can be administered to a patient at a location proximal the identified collector duct, or collector channel, locations. The therapeutic agent can include, but is not limited to, pharmaceutical agents, biological agents including hormones, enzyme or antibody-related components, oligonucleotides, DNA/RNA vectors and live cells configured to produce one or more biological components. The therapeutic agent can be configured to cause a reduction in the intraocular pressure of the eye.


In some embodiments, the implant may comprise a surface coated by a material selected from Teflon, polyimide, hydrogel, heparin, hydrophilic compound, anti-angiogenic factor, anti-proliferative factor, therapeutic drugs, and the like. Suitable anti-angiogenic or anti-proliferative factors may be selected from, for example, protamine, heparin, steroids, anti-invasive factor, retinoic acids and derivatives thereof, and paclitaxel or its analogues or derivatives thereof.


Implantation



FIG. 6 illustrates an embodiment of a method for delivering implants at or near a collector duct identified by the blood reflux produced in Schlemm's canal. The distal rim surface 39 of the rotor member 32 of the handheld peristaltic rotor device 30 can be placed over the surface subject's eye such that the plurality of compression elements 37 occludes one or more episcleral veins, thereby allowing an ophthalmologist or other practitioner to access the temporal side of the eye through the undercut 45 of the rotor member 32. For example, the ophthalmologist can form an incision, including a small, self-sealing (e.g., less than 1 mm) incision in the cornea 12 on the temporal side of the eye, insert a delivery instrument 50 carrying an implant 51 into the incision, advance the delivery instrument across the anterior chamber and deliver the implant 51 near an identified collector duct.


In other embodiments, the peristaltic rotor device 30 can be oriented such that the plurality of compression elements 37 occludes one or more episcleral veins on a temporal side of the eye and the implant 51 can be delivered to the temporal side of the eye via an incision. In some embodiments, the delivery instrument 50 can be configured to carry multiple implants and to deliver the implants at various locations within the eye without removing the delivery instrument 50.


The delivery instrument 50 can comprise any suitable instrument for delivery of intraocular implants within the eye, such as the delivery instruments described in U.S. Patent Publication No. 2008/0228127, U.S. Patent Publication No. 2013/0253528, or U.S. patent application Ser. No. 16/132,252, the entire content of each of which is hereby expressly incorporated by reference herein. For example, the delivery instrument can comprise a cannula portion 55. The distal section of the cannula portion 55 can include a distal space 56 for holding an implant 51. The proximal end 57 of the lumen of the distal space 56 can be sealed from the remaining lumen of the cannula portion 55. In some embodiments, the delivery instrument 50 can comprise a microknife, a pointed guidewire, a sharpened applicator, a screw shaped applicator, an irrigating applicator, or a barbed applicator. In other embodiments, the incision can be formed by a blade, scalpel, or other suitable instrument or by retrograde fiberoptic laser ablation and the delivery instrument 50 can then be inserted through the preformed incision.



FIG. 7 illustrates a perspective view of the anterior chamber angle of an eye 10 with the implant 51 having been positioned near an identified collector duct 27 within Schlemm's canal 22. The inlet end of the implant 51 is exposed to the anterior chamber 20 while the outlet end is positioned within an inner wall 58 of Schlemm's canal 22 near the collector duct 27. In some embodiments, the outlet end of the implant is positioned within 1 mm of the identified location of the collector duct 27. In a further embodiment, the outlet end may be positioned within the collector duct 27. The implant 51 can be positioned to maintain a fluid passageway from the anterior chamber 20 to a location near the collector duct 27.


Conditional language, for example, among others, “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers or an amount that is within less than or equal to 10% of the stated amount. For example, “about 10 mm” includes “10 mm.” Terms or phrases preceded by a term such as “substantially” or “generally” include the recited term or phrase. For example, “substantially transparent” includes “transparent.” The terms “comprising,” “including,”, “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.


While the inventions have been discussed in the context of certain embodiments and examples, it should be appreciated that the inventions extend beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the inventions and obvious modifications and equivalents thereof. Some embodiments have been described in connection with the accompanying drawings. However, it should be understood that the figures are not drawn to scale. Distances, angles, etc. are merely illustrative and do not necessarily bear an exact relationship to actual dimensions and layout of the devices illustrated. Components can be added, removed, and/or rearranged. Additionally, the skilled artisan will recognize that any of the above-described methods can be carried out using any appropriate apparatus. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with various embodiments can be used in all other embodiments set forth herein. The headings used herein are merely provided to enhance readability and are not intended to limit the scope of the embodiments disclosed in a particular section to the features or elements disclosed in that section.


For purposes of this disclosure, certain aspects, advantages, and novel features of the invention are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves one advantage or group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.

Claims
  • 1. A handheld peristaltic rotor device for locating collector ducts of Schlemm's canal of an eye, the handheld peristaltic rotor device comprising: a rotor having a proximal portion and a distal open end, the distal open end comprising a distal rim surface and a corneal clearance portion;a plurality of compression elements protruding from the distal rim surface; anda handle connected to the proximal portion of the rotor to facilitate manual rotation of the rotor, the handle comprising an elongated rod of rigid material,wherein the rotor and the plurality of compression elements are configured to cause a blood reflux into Schlemm's canal from one or more occluded episcleral surface regions of an eye by positioning the rotor on an episcleral surface of the eye and rotating the rotor.
  • 2. The rotor device of claim 1, wherein the corneal clearance portion is configured to substantially conform to the episcleral surface of the eye.
  • 3. The rotor device of claim 1, wherein the rotor comprises a plurality of anti-suction vents configured to allow passage of air from a distal surface to an external surface of the rotor.
  • 4. The rotor device of claim 1, wherein the plurality of compression elements comprises a plurality of concentric spiral protrusions.
  • 5. The rotor device of claim 1, wherein the plurality of compression elements taper in height along their length.
  • 6. The rotor device of claim 1, wherein the plurality of compression elements are formed of a compliant polymeric material.
  • 7. The rotor device of claim 1, further comprising an optical portion comprising a magnifying lens to facilitate visualization of reflux.
  • 8. The rotor device of claim 7, wherein the optical portion is detachably coupled to the proximal portion of the rotor.
  • 9. The rotor device of claim 7, further comprising a spring having a first end coupled to the optical portion and a second end coupled to the proximal portion of the rotor, wherein the spring is configured to cause rotation of the rotor.
  • 10. A handheld peristaltic rotor device for locating collector ducts of Schlemm's canal of an eye, the handheld peristaltic rotor device comprising: a proximal handle comprising an elongated rod of rigid material;a distal rotor member having a proximal end and a distal open end,wherein the distal open end of the distal rotor member comprises a distal rim surface comprising a plurality of compression elements protruding from the distal rim surface and a corneal clearance portion,wherein the proximal end of the distal rotor member comprises a plurality of anti-suction vents configured to allow passage of air from the corneal clearance portion to an external surface of the proximal end of the distal rotor member,wherein the plurality of compression elements is configured to apply pressure to an episcleral surface region of the eye, thereby occluding one or more episcleral veins to produce blood reflux within Schlemm's canal, andwherein a distal end of the proximal handle is coupled to the proximal end of the distal rotor member to facilitate manual rotation of the distal rotor member.
  • 11. The rotor device of claim 10, wherein the corneal clearance portion is configured to substantially conform to the episcleral surface region of the eye.
  • 12. The rotor device of claim 10, wherein the plurality of compression elements comprises a plurality of concentric spiral protrusions.
  • 13. The rotor device of claim 10, wherein the plurality of compression elements comprises a plurality of ribs.
  • 14. The rotor device of claim 10, wherein the plurality of compression elements comprises a plurality of spoke-shaped protrusion extending outward from the distal rotor member.
  • 15. The rotor device of claim 10, wherein the plurality of compression elements taper in height along their length.
  • 16. The rotor device of claim 10, wherein the plurality of compression elements are formed of a compliant polymeric material.
  • 17. The rotor device of claim 10, further comprising an optical portion comprising a magnifying lens to facilitate visualization of reflux.
  • 18. The rotor device of claim 17, wherein the optical portion is detachably coupled to the proximal portion of the rotor.
  • 19. The rotor device of claim 17, further comprising an internally wound spring having a first end coupled to the optical portion and a second end coupled to the proximal portion of the rotor, wherein the spring is configured to cause rotation of the rotor.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/564,972 filed Sep. 28, 2017, the entire content of which is hereby incorporated by reference herein.

US Referenced Citations (733)
Number Name Date Kind
2031754 Mills Feb 1936 A
2127903 Bowen Aug 1938 A
2269963 Frederick Jan 1942 A
3159161 Ness Dec 1964 A
3416530 Ness Dec 1968 A
3439675 Cohen Apr 1969 A
3717151 Collett Feb 1973 A
3788327 Donowitz et al. Jan 1974 A
3827700 Kaller Aug 1974 A
3863623 Trueblood et al. Feb 1975 A
3915172 Krejci et al. Oct 1975 A
3948271 Aklyama Apr 1976 A
3948871 Butterfield et al. Apr 1976 A
3976077 Kerfoot, Jr. Aug 1976 A
4030480 Meyer Jun 1977 A
4037604 Newkirk Jul 1977 A
4043346 Mobley et al. Aug 1977 A
4113088 Binkhorst Sep 1978 A
4168697 Cantekin Sep 1979 A
4175563 Arenberg et al. Nov 1979 A
4299227 Lincoff Nov 1981 A
4366582 Faulkner Jan 1983 A
4402681 Haas et al. Sep 1983 A
4428746 Mendez Jan 1984 A
4449529 Burns et al. May 1984 A
4449974 Messingschlager May 1984 A
4457757 Molteno Jul 1984 A
4501274 Skjaerpe Feb 1985 A
4554918 White Nov 1985 A
4560383 Leiske Dec 1985 A
4578058 Grandon Mar 1986 A
4604087 Joseph Aug 1986 A
4632842 Karwoski et al. Dec 1986 A
4634418 Binder Jan 1987 A
4642090 Ultrata Feb 1987 A
4692142 Dignam et al. Sep 1987 A
4718907 Karwoski et al. Jan 1988 A
4722724 Schocket Feb 1988 A
4733665 Palmaz Mar 1988 A
4750901 Molteno Jun 1988 A
4782819 Adair Nov 1988 A
4787885 Binder Nov 1988 A
4800870 Reid, Jr. Jan 1989 A
4800890 Cramer Jan 1989 A
4804382 Turina et al. Feb 1989 A
4820626 Williams et al. Apr 1989 A
4826478 Schocket May 1989 A
4846172 Berlin Jul 1989 A
4846793 Leonard et al. Jul 1989 A
4867173 Leoni Sep 1989 A
4870953 DonMicheal et al. Oct 1989 A
4886488 White Dec 1989 A
4900300 Lee Feb 1990 A
4905667 Foerster et al. Mar 1990 A
4936825 Ungerleider Jun 1990 A
4946436 Smith Aug 1990 A
4968296 Ritch et al. Nov 1990 A
4986810 Semrad Jan 1991 A
4991602 Amplatz et al. Feb 1991 A
5005577 Frenekl Apr 1991 A
5041081 Odrich Aug 1991 A
5053040 Goldsmith, III Oct 1991 A
5053044 Mueller et al. Oct 1991 A
5073163 Lippman Dec 1991 A
5092837 Ritch et al. Mar 1992 A
5095887 Leon et al. Mar 1992 A
5116327 Seder et al. May 1992 A
5127901 Odrich Jul 1992 A
5129895 Vassiliadis et al. Jul 1992 A
5139502 Berg et al. Aug 1992 A
5169386 Becker et al. Dec 1992 A
5171213 Price, Jr. Dec 1992 A
5178604 Baerveldt et al. Jan 1993 A
5180362 Worst Jan 1993 A
5207685 Cinberg et al. May 1993 A
5221255 Mahurkar et al. Jun 1993 A
5246451 Trescony et al. Sep 1993 A
5248231 Denham et al. Sep 1993 A
5284476 Koch Feb 1994 A
5290295 Querals et al. Mar 1994 A
5300020 L'Esperance, Jr. Apr 1994 A
5318513 Leib et al. Jun 1994 A
5324306 Makower et al. Jun 1994 A
5326345 Price, Jr. Jul 1994 A
5334137 Freeman Aug 1994 A
5338291 Speckman et al. Aug 1994 A
5342370 Simon et al. Aug 1994 A
5346464 Camras Sep 1994 A
5358492 Feibus Oct 1994 A
5360399 Stegmann Nov 1994 A
5370607 Memmen Dec 1994 A
5370641 O'Donnell, Jr. Dec 1994 A
5372577 Ungerleider Dec 1994 A
5397300 Baerveldt et al. Mar 1995 A
5415666 Gourlay et al. May 1995 A
5433701 Rubinstein Jul 1995 A
5445637 Bretton Aug 1995 A
5454796 Krupin Oct 1995 A
5462558 Kolesa et al. Oct 1995 A
5472440 Beckman Dec 1995 A
5476445 Baerveldt et al. Dec 1995 A
5486165 Stegmann Jan 1996 A
5520631 Nordquist et al. May 1996 A
5556400 Tunis Sep 1996 A
5558629 Baerveldt et al. Sep 1996 A
5558630 Fisher Sep 1996 A
5558637 Allonen et al. Sep 1996 A
5562641 Flomenblit et al. Oct 1996 A
RE35390 Smith Dec 1996 E
5626558 Suson May 1997 A
5626559 Solomon May 1997 A
5639278 Dereume et al. Jun 1997 A
5643321 McDevitt Jul 1997 A
5651782 Simon et al. Jul 1997 A
5651783 Reynard Jul 1997 A
5653724 Imonti Aug 1997 A
5669501 Hissong et al. Sep 1997 A
5676679 Simon et al. Oct 1997 A
5681275 Ahmed Oct 1997 A
5681323 Arick Oct 1997 A
5695479 Jagpal Dec 1997 A
5702414 Richter et al. Dec 1997 A
5702419 Berry et al. Dec 1997 A
5704907 Nordquist et al. Jan 1998 A
5713844 Peyman Feb 1998 A
5722948 Gross Mar 1998 A
5723005 Herrick Mar 1998 A
5725529 Nicholson et al. Mar 1998 A
5725546 Samson Mar 1998 A
5733256 Costin Mar 1998 A
5741292 Mendius Apr 1998 A
5741333 Frid Apr 1998 A
5743868 Brown et al. Apr 1998 A
5752928 de Roulhac et al. May 1998 A
5762625 Igaki Jun 1998 A
5766243 Christensen et al. Jun 1998 A
5785674 Mateen Jul 1998 A
5792099 DeCamp et al. Aug 1998 A
5800376 Vaskelis Sep 1998 A
5807244 Barot Sep 1998 A
5807302 Wandel Sep 1998 A
5810870 Myers et al. Sep 1998 A
5817100 Igaki Oct 1998 A
5824071 Nelson et al. Oct 1998 A
5830171 Wallace Nov 1998 A
5833694 Poncet Nov 1998 A
5836939 Negus et al. Nov 1998 A
5846199 Hijlkema et al. Dec 1998 A
5865831 Cozean et al. Feb 1999 A
5868697 Richter et al. Feb 1999 A
5879319 Pynson et al. Mar 1999 A
5882327 Jacob Mar 1999 A
5891084 Lee Apr 1999 A
5893837 Eagles et al. Apr 1999 A
5908449 Bruchman et al. Jun 1999 A
5913852 Magram Jun 1999 A
5927585 Moorman et al. Jul 1999 A
5932299 Katoot Aug 1999 A
5941250 Aramant et al. Aug 1999 A
5984913 Kritzinger et al. Nov 1999 A
6004302 Brierley Dec 1999 A
6007510 Nigam Dec 1999 A
6007511 Prywes Dec 1999 A
6030416 Huo et al. Feb 2000 A
6033434 Borghi Mar 2000 A
6036678 Giungo Mar 2000 A
6036682 Lange et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6050970 Baeverldt Apr 2000 A
6050999 Paraschac et al. Apr 2000 A
6071286 Mawad Jun 2000 A
6074395 Trott et al. Jun 2000 A
6077299 Adelberg et al. Jun 2000 A
6102045 Nordquist et al. Aug 2000 A
6135977 Drasler et al. Oct 2000 A
6142990 Burk Nov 2000 A
6146387 Trott et al. Nov 2000 A
6165210 Lau et al. Dec 2000 A
6168575 Soltanpour Jan 2001 B1
6174305 Mikus et al. Jan 2001 B1
6186974 Allan et al. Feb 2001 B1
6187016 Hedges et al. Feb 2001 B1
6221078 Bylsma Apr 2001 B1
6224570 Le et al. May 2001 B1
6231597 Deem et al. May 2001 B1
6241721 Cozean et al. Jun 2001 B1
6254612 Hieshima Jul 2001 B1
6261256 Ahmed Jul 2001 B1
6264668 Prywes Jul 2001 B1
6287313 Sasso Sep 2001 B1
6299603 Hecker et al. Oct 2001 B1
6306114 Freeman et al. Oct 2001 B1
6342058 Portney Jan 2002 B1
6355033 Moorman et al. Mar 2002 B1
6358222 Grundei Mar 2002 B1
6361519 Knudson et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6375642 Grieshaber et al. Apr 2002 B1
6378526 Bowman Apr 2002 B1
6402734 Weiss Jun 2002 B1
6405732 Edwards et al. Jun 2002 B1
6428501 Reynard Aug 2002 B1
6428566 Holt Aug 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6450984 Lynch et al. Sep 2002 B1
6454787 Maddalo et al. Sep 2002 B1
6464724 Lynch et al. Oct 2002 B1
6468283 Richter et al. Oct 2002 B1
6494857 Neuhann Dec 2002 B1
6508779 Suson Jan 2003 B1
6524275 Lynch et al. Feb 2003 B1
6530896 Elliott Mar 2003 B1
6533768 Hill Mar 2003 B1
6544249 Yu et al. Apr 2003 B1
6561974 Grieshaber et al. May 2003 B1
6582426 Moorman et al. Jun 2003 B2
6582453 Tran et al. Jun 2003 B1
6585680 Bugge Jul 2003 B2
6585753 Eder et al. Jul 2003 B2
6589198 Soltanpour et al. Jul 2003 B1
6589203 Mitrev Jul 2003 B1
6595945 Brown Jul 2003 B2
6605053 Kamm et al. Aug 2003 B1
6607542 Wild Aug 2003 B1
6613343 Dillingham et al. Sep 2003 B2
6620154 Amirkhanian et al. Sep 2003 B1
6623283 Torigian et al. Sep 2003 B1
6626858 Lynch et al. Sep 2003 B2
6629981 Bui et al. Oct 2003 B2
6638239 Bergheim et al. Oct 2003 B1
6666213 Svadovskiy Dec 2003 B2
6666841 Gharib et al. Dec 2003 B2
6676607 De Juan, Jr. et al. Jan 2004 B2
6682500 Soltanpour et al. Jan 2004 B2
6699211 Savage Mar 2004 B2
6699272 Slepian et al. Mar 2004 B2
D490152 Myall et al. May 2004 S
6730056 Ghaem et al. May 2004 B1
6736791 Tu et al. May 2004 B1
6763833 Khera et al. Jul 2004 B1
6764439 Schaaf et al. Jul 2004 B2
6767346 Damasco et al. Jul 2004 B2
6780164 Bergheim et al. Aug 2004 B2
6780165 Kadziauskas et al. Aug 2004 B2
6783544 Lynch et al. Aug 2004 B2
6827699 Lynch et al. Dec 2004 B2
6827700 Lynch et al. Dec 2004 B2
6827738 Willis et al. Dec 2004 B2
6893413 Martin May 2005 B2
6902577 Lipshitz et al. Jun 2005 B2
6939298 Brown et al. Sep 2005 B2
6955656 Bergheim et al. Oct 2005 B2
6962573 Wilcox Nov 2005 B1
6966888 Cullen et al. Nov 2005 B2
6981958 Gharib et al. Jan 2006 B1
7077821 Durgin Jul 2006 B2
7077848 de Juan et al. Jul 2006 B1
7090681 Weber et al. Aug 2006 B2
7094225 Tu et al. Aug 2006 B2
7101402 Phelps et al. Sep 2006 B2
7135009 Tu et al. Nov 2006 B2
7135016 Asia et al. Nov 2006 B1
7144616 Unger et al. Dec 2006 B1
7163543 Smedley et al. Jan 2007 B2
7186232 Smedley et al. Mar 2007 B1
7192412 Zhou et al. Mar 2007 B1
7192484 Chappa et al. Mar 2007 B2
7217263 Humayun et al. May 2007 B2
7220238 Lynch et al. May 2007 B2
7273475 Tu et al. Sep 2007 B2
7294115 Wilk Nov 2007 B1
7297130 Bergheim et al. Nov 2007 B2
7331984 Tu et al. Feb 2008 B2
7344528 Tu et al. Mar 2008 B1
7364564 Sniegowski et al. Apr 2008 B2
7431710 Tu et al. Oct 2008 B2
7468065 Weber et al. Dec 2008 B2
7488303 Haffner et al. Feb 2009 B1
7520876 Ressemann et al. Apr 2009 B2
D592746 Highley et al. May 2009 S
RE40722 Chappa Jun 2009 E
7563241 Tu et al. Jul 2009 B2
D606190 Pruitt et al. Dec 2009 S
7641627 Camras et al. Jan 2010 B2
7678065 Haffner et al. Mar 2010 B2
7695135 Rosenthal Apr 2010 B1
7708711 Tu et al. May 2010 B2
7713228 Robin May 2010 B2
7758624 Dorn et al. Jul 2010 B2
7771388 Olsen et al. Aug 2010 B2
7811268 Maldon Ado Bas Oct 2010 B2
7850637 Lynch et al. Dec 2010 B2
7857782 Tu et al. Dec 2010 B2
7862531 Yaron et al. Jan 2011 B2
7867186 Haffner et al. Jan 2011 B2
7867205 Bergheim et al. Jan 2011 B2
7879001 Haffner et al. Feb 2011 B2
7879079 Tu et al. Feb 2011 B2
7905904 Stone et al. Mar 2011 B2
7931660 Aranyi et al. Apr 2011 B2
7945336 Sauter-Starace et al. May 2011 B2
7951155 Smedley et al. May 2011 B2
7959632 Fugo Jun 2011 B2
7967772 McKenzie et al. Jun 2011 B2
7997460 Pardes et al. Aug 2011 B2
8007459 Haffner et al. Aug 2011 B2
D645489 Gille et al. Sep 2011 S
D645490 Gille et al. Sep 2011 S
8034016 Yaron et al. Oct 2011 B2
8034105 Stegmann et al. Oct 2011 B2
8062244 Tu et al. Nov 2011 B2
8070290 Gille et al. Dec 2011 B2
8075511 Tu et al. Dec 2011 B2
8118768 Tu et al. Feb 2012 B2
8142364 Haffner et al. Mar 2012 B2
8152752 Lynch et al. Apr 2012 B2
8197418 Lal et al. Jun 2012 B2
8267882 Euteneuer et al. Sep 2012 B2
8267995 Castillejos Sep 2012 B2
8273050 Bergheim et al. Sep 2012 B2
8333742 Bergheim et al. Dec 2012 B2
8337445 Tu et al. Dec 2012 B2
8348877 Tu et al. Jan 2013 B2
8388568 Lynch et al. Mar 2013 B2
8419673 Rickard Apr 2013 B2
8439972 Badawi et al. May 2013 B2
8506515 Burns et al. Aug 2013 B2
8540659 Berlin Sep 2013 B2
8545431 Rickard Oct 2013 B2
8579846 Tu et al. Nov 2013 B2
8579848 Field et al. Nov 2013 B2
8585631 Dacquay Nov 2013 B2
8585664 Dos Santos et al. Nov 2013 B2
8603024 Bohm et al. Dec 2013 B2
8617094 Smedley et al. Dec 2013 B2
8656958 Unger et al. Feb 2014 B2
8679089 Berlin Mar 2014 B2
8721580 Rickard et al. May 2014 B2
8753305 Field et al. Jun 2014 B2
8771217 Lynch et al. Jul 2014 B2
8771220 Nissan Jul 2014 B2
8801648 Bergheim et al. Aug 2014 B2
8808219 Bergheim et al. Aug 2014 B2
8808224 Rickard Aug 2014 B2
8814820 Bergheim et al. Aug 2014 B2
8840578 Dos Santos et al. Sep 2014 B2
8852137 Horvath et al. Oct 2014 B2
8852266 Brooks et al. Oct 2014 B2
8864701 Dos Santos et al. Oct 2014 B2
8882781 Smedley et al. Nov 2014 B2
8956320 Ovchinnikov et al. Feb 2015 B2
8986240 Dos Santos et al. Mar 2015 B2
8998838 Yalamanchili Apr 2015 B2
8998983 Auld Apr 2015 B2
9066782 Tu et al. Jun 2015 B2
9072588 Bohm et al. Jul 2015 B2
9125721 Field Sep 2015 B2
9132034 Dos Santos Sep 2015 B2
9155653 Field Oct 2015 B2
9155654 Tu et al. Oct 2015 B2
9173775 Haffner et al. Nov 2015 B2
9220632 Smedley et al. Dec 2015 B2
9226851 Gunn Jan 2016 B2
9283115 Lind et al. Mar 2016 B2
9289324 Johnson et al. Mar 2016 B2
9301875 Tu et al. Apr 2016 B2
9492320 Lynch et al. Nov 2016 B2
9554940 Haffner et al. Jan 2017 B2
9561131 Tu et al. Feb 2017 B2
9572963 Tu et al. Feb 2017 B2
9592151 Rangel-Friedman et al. Mar 2017 B2
9597230 Haffner et al. Mar 2017 B2
9603738 Haffner et al. Mar 2017 B2
9603741 Berlin Mar 2017 B2
9636255 Haffner et al. May 2017 B2
9668915 Haffner et al. Jun 2017 B2
9730638 Haffner et al. Aug 2017 B2
9789001 Tu et al. Oct 2017 B2
9827143 Lynch Nov 2017 B2
9833357 Berlin Dec 2017 B2
9849027 Highley et al. Dec 2017 B2
9962290 Burns et al. May 2018 B2
9987472 Tu et al. Jun 2018 B2
9993368 Bergheim et al. Jun 2018 B2
D833008 Kalina, Jr. et al. Nov 2018 S
10188551 Rangel-Friedman et al. Jan 2019 B2
10206813 Haffner et al. Feb 2019 B2
D846738 Kalina, Jr. et al. Apr 2019 S
10245178 Heitzmann et al. Apr 2019 B1
10271989 Haffner et al. Apr 2019 B2
10285853 Rangel-Friedman et al. May 2019 B2
10285856 Tu et al. May 2019 B2
10406029 Tu et al. Sep 2019 B2
10485701 Haffner et al. Nov 2019 B2
10485702 Bergheim et al. Nov 2019 B2
10492950 Lynch et al. Dec 2019 B2
10499809 Kalina, Jr. et al. Dec 2019 B2
10517759 Crimaldi et al. Dec 2019 B2
10568762 Lynch et al. Feb 2020 B2
D886997 Kalina, Jr. et al. Jun 2020 S
10674906 Kalina, Jr. et al. Jun 2020 B2
10813789 Haffner et al. Oct 2020 B2
D901683 Kalina, Jr. et al. Nov 2020 S
10828195 Burns et al. Nov 2020 B2
10828473 Haffner et al. Nov 2020 B2
20010000527 Yaron et al. Apr 2001 A1
20010025150 de Juan et al. Sep 2001 A1
20010053873 Schaaf et al. Dec 2001 A1
20020013546 Grieshaber et al. Jan 2002 A1
20020013572 Berlin Jan 2002 A1
20020026200 Savage Feb 2002 A1
20020052640 Bigus et al. May 2002 A1
20020072673 Yamamoto et al. Jun 2002 A1
20020082591 Haefliger Jun 2002 A1
20020087111 Ethier et al. Jul 2002 A1
20020099434 Buscemi et al. Jul 2002 A1
20020111608 Baerveldt et al. Aug 2002 A1
20020120284 Schachar et al. Aug 2002 A1
20020120285 Schachar et al. Aug 2002 A1
20020133168 Smedley et al. Sep 2002 A1
20020143284 Tu et al. Oct 2002 A1
20020156413 Williams et al. Oct 2002 A1
20020165522 Holmen Nov 2002 A1
20020169468 Brown Nov 2002 A1
20020177856 Richter et al. Nov 2002 A1
20020193725 Odrich Dec 2002 A1
20030014021 Holmen Jan 2003 A1
20030014092 Neuhann Jan 2003 A1
20030019833 Unger et al. Jan 2003 A1
20030055372 Lynch et al. Mar 2003 A1
20030060752 Bergheim et al. Mar 2003 A1
20030079329 Yaron et al. May 2003 A1
20030093084 Nissan et al. May 2003 A1
20030097117 Buono May 2003 A1
20030097151 Smedley et al. May 2003 A1
20030105456 Lin Jun 2003 A1
20030109907 Shadduck Jun 2003 A1
20030135149 Cullen et al. Jul 2003 A1
20030139729 Stegmann et al. Jul 2003 A1
20030153863 Patel Aug 2003 A1
20030181848 Bergheim et al. Sep 2003 A1
20030187384 Bergheim et al. Oct 2003 A1
20030195438 Petillo Oct 2003 A1
20030208163 Yaron et al. Nov 2003 A1
20030208217 Dan Nov 2003 A1
20030212383 Cote et al. Nov 2003 A1
20030229303 Haffner et al. Dec 2003 A1
20030236483 Ren Dec 2003 A1
20030236484 Lynch et al. Dec 2003 A1
20040024345 Gharib et al. Feb 2004 A1
20040059248 Messner et al. Mar 2004 A1
20040076676 Tojo et al. Apr 2004 A1
20040088048 Richter et al. May 2004 A1
20040092856 Dahan May 2004 A1
20040098122 Lee et al. May 2004 A1
20040111050 Smedley et al. Jun 2004 A1
20040147870 Burns et al. Jul 2004 A1
20040154946 Solovay et al. Aug 2004 A1
20040162545 Brown et al. Aug 2004 A1
20040193095 Shadduck Sep 2004 A1
20040193262 Shadduck Sep 2004 A1
20040210181 Vass et al. Oct 2004 A1
20040210185 Tu et al. Oct 2004 A1
20040215126 Ahmed Oct 2004 A1
20040216749 Tu Nov 2004 A1
20040236343 Taylor et al. Nov 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040249404 Haefliger Dec 2004 A1
20040254517 Quiroz-Mercado et al. Dec 2004 A1
20040254519 Tu et al. Dec 2004 A1
20040254520 Porteous et al. Dec 2004 A1
20040254521 Simon Dec 2004 A1
20040260227 Lisk, Jr. et al. Dec 2004 A1
20040260228 Lynch et al. Dec 2004 A1
20050038498 Dubrow et al. Feb 2005 A1
20050049578 Tu et al. Mar 2005 A1
20050055075 Pinchuk et al. Mar 2005 A1
20050096639 Slatkine et al. May 2005 A1
20050119601 Lynch et al. Jun 2005 A9
20050119737 Bene et al. Jun 2005 A1
20050125003 Pinchuk et al. Jun 2005 A1
20050165385 Simon Jul 2005 A1
20050171507 Christian et al. Aug 2005 A1
20050171562 Criscuolo et al. Aug 2005 A1
20050182350 Nigam Aug 2005 A1
20050184004 Rodgers et al. Aug 2005 A1
20050192527 Gharib et al. Sep 2005 A1
20050209549 Bergheim et al. Sep 2005 A1
20050209672 George et al. Sep 2005 A1
20050240143 Dohlman Oct 2005 A1
20050240222 Shipp Oct 2005 A1
20050250788 Tu et al. Nov 2005 A1
20050261624 Wilcox Nov 2005 A1
20050267397 Bhalla Dec 2005 A1
20050267398 Protopsaltis et al. Dec 2005 A1
20050267478 Corradi et al. Dec 2005 A1
20050273033 Grahn et al. Dec 2005 A1
20050277864 Haffner et al. Dec 2005 A1
20050288619 Savage Dec 2005 A1
20060032507 Tu Feb 2006 A1
20060036207 Koonmen et al. Feb 2006 A1
20060074375 Bergheim et al. Apr 2006 A1
20060079828 Brown Apr 2006 A1
20060084907 Bergheim et al. Apr 2006 A1
20060106370 Baerveldt et al. May 2006 A1
20060116626 Smedley et al. Jun 2006 A1
20060129129 Smith Jun 2006 A1
20060155300 Stamper et al. Jul 2006 A1
20060173397 Tu et al. Aug 2006 A1
20060195055 Bergheim et al. Aug 2006 A1
20060195056 Bergheim et al. Aug 2006 A1
20060200113 Haffner et al. Sep 2006 A1
20060210605 Chang et al. Sep 2006 A1
20060217741 Ghannoum Sep 2006 A1
20060235367 Takashima et al. Oct 2006 A1
20060241580 Mittelstein et al. Oct 2006 A1
20060276739 Brown Dec 2006 A1
20070004998 Rodgers et al. Jan 2007 A1
20070021653 Hattenbach et al. Jan 2007 A1
20070073275 Conston et al. Mar 2007 A1
20070073390 Lee Mar 2007 A1
20070078371 Brown et al. Apr 2007 A1
20070078471 Schachar et al. Apr 2007 A1
20070088432 Solovay et al. Apr 2007 A1
20070093740 Shetty Apr 2007 A1
20070106199 Krivoy et al. May 2007 A1
20070106200 Levy May 2007 A1
20070118065 Pinchuk et al. May 2007 A1
20070118066 Pinchuk et al. May 2007 A1
20070123812 Pinchuk et al. May 2007 A1
20070123919 Schachar et al. May 2007 A1
20070149927 Itou et al. Jun 2007 A1
20070154621 Raad Jul 2007 A1
20070156079 Brown Jul 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070179426 Selden Aug 2007 A1
20070179471 Christian et al. Aug 2007 A1
20070185468 Prywes Aug 2007 A1
20070191863 De Juan et al. Aug 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070212386 Patravale et al. Sep 2007 A1
20070212387 Patravale et al. Sep 2007 A1
20070212388 Patravale et al. Sep 2007 A1
20070212393 Patravale et al. Sep 2007 A1
20070219632 Castillejos Sep 2007 A1
20070260201 Prausnitz et al. Nov 2007 A1
20070282244 Tu et al. Dec 2007 A1
20070282245 Tu et al. Dec 2007 A1
20070287958 McKenzie et al. Dec 2007 A1
20070292470 Thornton Dec 2007 A1
20070292474 Hsu et al. Dec 2007 A1
20070293807 Lynch et al. Dec 2007 A1
20070293872 Peyman Dec 2007 A1
20070293873 Chang Dec 2007 A1
20070298068 Badawi et al. Dec 2007 A1
20080027304 Pardo et al. Jan 2008 A1
20080033351 Trogden et al. Feb 2008 A1
20080039931 Jelle et al. Feb 2008 A1
20080045878 Bergheim et al. Feb 2008 A1
20080051681 Schwartz Feb 2008 A1
20080058704 Hee et al. Mar 2008 A1
20080082078 Berlin Apr 2008 A1
20080091224 Griffis, III et al. Apr 2008 A1
20080097214 Meyers et al. Apr 2008 A1
20080097335 Trogden et al. Apr 2008 A1
20080108932 Rodgers May 2008 A1
20080108933 Yu et al. May 2008 A1
20080108934 Berlin May 2008 A1
20080109037 Steiner et al. May 2008 A1
20080114440 Hlavka et al. May 2008 A1
20080125691 Yaron et al. May 2008 A1
20080140059 Schachar et al. Jun 2008 A1
20080147083 Vold et al. Jun 2008 A1
20080161741 Bene et al. Jul 2008 A1
20080161907 Chen et al. Jul 2008 A1
20080183289 Werblin Jul 2008 A1
20080188860 Vold Aug 2008 A1
20080200923 Beckman et al. Aug 2008 A1
20080208176 Loh Aug 2008 A1
20080210322 Unger et al. Sep 2008 A1
20080215062 Bowen et al. Sep 2008 A1
20080221501 Cote et al. Sep 2008 A1
20080236669 Unger et al. Oct 2008 A1
20080243156 John Oct 2008 A1
20080243243 Williams et al. Oct 2008 A1
20080243247 Poley et al. Oct 2008 A1
20080255545 Mansfield et al. Oct 2008 A1
20080269730 Dotson Oct 2008 A1
20080277007 Unger et al. Nov 2008 A1
20080281250 Bergsneider et al. Nov 2008 A1
20080289710 Unger et al. Nov 2008 A1
20080306429 Shields et al. Dec 2008 A1
20090036818 Grahn et al. Feb 2009 A1
20090043242 Bene et al. Feb 2009 A1
20090043321 Conston et al. Feb 2009 A1
20090043365 Friedland et al. Feb 2009 A1
20090076436 Gharib et al. Mar 2009 A2
20090082860 Schieber et al. Mar 2009 A1
20090082862 Schieber et al. Mar 2009 A1
20090082863 Schieber et al. Mar 2009 A1
20090112245 Haefliger Apr 2009 A1
20090124973 D'Agostino et al. May 2009 A1
20090132040 Frion et al. May 2009 A1
20090137989 Kataoka May 2009 A1
20090137992 Mallakrishnan May 2009 A1
20090151422 Unger et al. Jun 2009 A1
20090177138 Brown et al. Jul 2009 A1
20090182421 Silvestrini et al. Jul 2009 A1
20090198213 Tanaka Aug 2009 A1
20090204053 Nissan et al. Aug 2009 A1
20090227933 Karageozian Sep 2009 A1
20090227934 Eutenever et al. Sep 2009 A1
20090264813 Chang Oct 2009 A1
20090275924 Lattanzio et al. Nov 2009 A1
20090287136 Castillejos Nov 2009 A1
20090287233 Huculak Nov 2009 A1
20090326432 Schmidt et al. Dec 2009 A1
20100004635 Lin et al. Jan 2010 A1
20100025613 Tai et al. Feb 2010 A1
20100042209 Guarnieri Feb 2010 A1
20100056977 Wandel Mar 2010 A1
20100056979 Smedley et al. Mar 2010 A1
20100057055 Camras et al. Mar 2010 A1
20100114006 Baerveldt May 2010 A1
20100121342 Schieber et al. May 2010 A1
20100125237 Schocket May 2010 A1
20100168644 Brown Jul 2010 A1
20100175767 Unger et al. Jul 2010 A1
20100185138 Yaron et al. Jul 2010 A1
20100191103 Stamper et al. Jul 2010 A1
20100191329 Badawi et al. Jul 2010 A1
20100222733 Schieber et al. Sep 2010 A1
20100234791 Lynch et al. Sep 2010 A1
20100241046 Pinchuk et al. Sep 2010 A1
20100249691 Van der Mooren et al. Sep 2010 A1
20100274259 Yaron et al. Oct 2010 A1
20110009874 Wardle et al. Jan 2011 A1
20110009958 Wardle et al. Jan 2011 A1
20110046536 Stegmann et al. Feb 2011 A1
20110046728 Shareef et al. Feb 2011 A1
20110066098 Stergiopulos Mar 2011 A1
20110071454 Dos Santos et al. Mar 2011 A1
20110071456 Rickard Mar 2011 A1
20110071458 Rickard Mar 2011 A1
20110071459 Rickard et al. Mar 2011 A1
20110071505 Rickard et al. Mar 2011 A1
20110098627 Wilcox Apr 2011 A1
20110098809 Wardle et al. Apr 2011 A1
20110118649 Stegmann et al. May 2011 A1
20110118835 Silvestrini et al. May 2011 A1
20110130831 Badawi et al. Jun 2011 A1
20110144559 Lafdi et al. Jun 2011 A1
20110196487 Badawi et al. Aug 2011 A1
20110224597 Stegmann et al. Sep 2011 A1
20110244014 Williams et al. Oct 2011 A1
20110245753 Sunalp Oct 2011 A1
20110248671 Dos Santos et al. Oct 2011 A1
20110257623 Marshall et al. Oct 2011 A1
20110319806 Wardle Dec 2011 A1
20120010702 Stegmann et al. Jan 2012 A1
20120022424 Yamamoto et al. Jan 2012 A1
20120035524 Silvestrini Feb 2012 A1
20120059461 Badawi et al. Mar 2012 A1
20120078158 Haffner et al. Mar 2012 A1
20120089072 Cunningham, Jr. Apr 2012 A1
20120089073 Cunningham, Jr. Apr 2012 A1
20120130467 Selden et al. May 2012 A1
20120179087 Schieber et al. Jul 2012 A1
20120184892 Bigler et al. Jul 2012 A1
20120203160 Kahook et al. Aug 2012 A1
20120257167 Gille et al. Oct 2012 A1
20120259195 Haffner et al. Oct 2012 A1
20120289883 Meng et al. Nov 2012 A1
20120302861 Marshall et al. Nov 2012 A1
20120310072 Grieshaber Dec 2012 A1
20120323159 Wardle et al. Dec 2012 A1
20130006164 Yaron et al. Jan 2013 A1
20130006165 Eutenener et al. Jan 2013 A1
20130018295 Haffner et al. Jan 2013 A1
20130018296 Bergheim et al. Jan 2013 A1
20130079701 Schieber et al. Mar 2013 A1
20130090534 Burns et al. Apr 2013 A1
20130102949 Baerveldt Apr 2013 A1
20130144202 Field et al. Jun 2013 A1
20130150770 Horvath et al. Jun 2013 A1
20130150773 Nissan et al. Jun 2013 A1
20130150774 Field et al. Jun 2013 A1
20130150776 Bohm et al. Jun 2013 A1
20130150777 Bohm et al. Jun 2013 A1
20130150779 Field Jun 2013 A1
20130150959 Shieber et al. Jun 2013 A1
20130158381 Rickard Jun 2013 A1
20130158462 Wardle et al. Jun 2013 A1
20130165840 Orge Jun 2013 A1
20130172804 Schieber et al. Jul 2013 A1
20130184631 Pinchuk Jul 2013 A1
20130253404 Tu Sep 2013 A1
20130253405 Tu Sep 2013 A1
20130281910 Tu et al. Oct 2013 A1
20130310930 Tu et al. Nov 2013 A1
20140034607 Meng et al. Feb 2014 A1
20140046437 Renke Feb 2014 A1
20140052046 Peartree et al. Feb 2014 A1
20150223981 Smedley et al. Aug 2015 A1
20150342875 Haffner Dec 2015 A1
20150374546 Hill Dec 2015 A1
20160354309 Heitzmann et al. Dec 2016 A1
20170135857 Haffner et al. May 2017 A1
20180021170 Haffner et al. Jan 2018 A1
20180028361 Haffner et al. Feb 2018 A1
20180085065 Haffner et al. Mar 2018 A1
20180161205 Tu et al. Jun 2018 A1
20180177633 Haffner et al. Jun 2018 A1
20180280194 Heitzmann et al. Oct 2018 A1
20180303665 Heitzmann et al. Oct 2018 A1
20180303752 Haffner Oct 2018 A1
20180333296 Heitzmann et al. Nov 2018 A1
20190000673 Fjield et al. Jan 2019 A1
20190021991 Heitzmann et al. Jan 2019 A9
20190053704 Burns et al. Feb 2019 A1
20190083307 Burns et al. Mar 2019 A1
20190104936 Gunn et al. Apr 2019 A1
20190105077 Kalina, Jr. et al. Apr 2019 A1
20190224046 Heitzmann et al. Jul 2019 A1
20190314199 Haffner et al. Oct 2019 A1
20190321220 Rangel-Friedman et al. Oct 2019 A1
20190321225 Smedley et al. Oct 2019 A1
20190321226 Haffner et al. Oct 2019 A1
20200155349 Haffner et al. May 2020 A1
20200179171 Crimaldi et al. Jun 2020 A1
20200214560 Kalina, Jr. et al. Jul 2020 A1
20200214561 Kalina, Jr. et al. Jul 2020 A1
20200367745 Kalina, Jr. et al. Nov 2020 A1
Foreign Referenced Citations (100)
Number Date Country
199876197 Feb 1999 AU
200072059 Jul 2001 AU
2004264913 Dec 2011 AU
2009251058 Dec 2013 AU
2244646 Feb 1999 CA
2442652 Jan 2011 CA
2683224 Dec 2014 CA
92111244 Jul 1993 CH
19840047 Mar 2000 DE
10127666 Jan 2003 DE
0858788 Aug 1998 EP
1977724 Oct 2008 EP
2260803 Dec 2010 EP
2260804 Dec 2010 EP
2263621 Dec 2010 EP
2351589 Aug 2011 EP
2982354 Feb 2016 EP
2985012 Feb 2016 EP
2967993 Apr 2019 EP
2553658 Apr 1985 FR
2710269 Mar 1995 FR
2721499 Dec 1995 FR
2757068 Jun 1998 FR
2296663 Jul 1996 GB
3703721 Jul 2005 JP
4031836 Jan 2008 JP
4688444 Feb 2011 JP
2012-198134 Sep 2012 JP
5255402 Apr 2013 JP
5323011 Jul 2013 JP
2013-208434 Oct 2013 JP
2014-193366 Oct 2014 JP
2014-240022 Dec 2014 JP
2022539 Nov 1994 RU
2143250 Dec 1999 RU
WO 198900869 Feb 1989 WO
WO 199118568 Dec 1991 WO
WO 199200112 Jan 1992 WO
WO 199413234 Jun 1994 WO
WO 199508310 Mar 1995 WO
WO 199823237 Jun 1998 WO
WO 1998030181 Jul 1998 WO
WO 199835639 Aug 1998 WO
WO 199837831 Sep 1998 WO
WO 199926567 Jun 1999 WO
WO 199930641 Jun 1999 WO
WO 200013627 Mar 2000 WO
WO 200064389 Nov 2000 WO
WO 200064390 Nov 2000 WO
WO 200064391 Nov 2000 WO
WO 200064393 Nov 2000 WO
WO 200067687 Nov 2000 WO
WO 200072788 Dec 2000 WO
WO 200141685 Jun 2001 WO
WO 200150943 Jul 2001 WO
WO 200178631 Oct 2001 WO
WO 200197727 Dec 2001 WO
WO 200236052 May 2002 WO
WO 2002074052 Sep 2002 WO
WO 2002080811 Oct 2002 WO
WO 2002087418 Nov 2002 WO
WO 2002089699 Nov 2002 WO
WO 2002102274 Dec 2002 WO
WO 2003015659 Feb 2003 WO
WO 2003041622 May 2003 WO
WO 2003045290 Jun 2003 WO
WO 2003073968 Sep 2003 WO
WO 2004014218 Feb 2004 WO
WO 2004043231 May 2004 WO
WO 2004093761 Nov 2004 WO
WO 2005016418 Feb 2005 WO
WO 2005105197 Nov 2005 WO
WO 2005107664 Nov 2005 WO
WO 2006036715 Apr 2006 WO
WO 2007130393 Nov 2007 WO
WO 2008061043 May 2008 WO
WO 2010077987 Jul 2010 WO
WO 2010093945 Aug 2010 WO
WO 2010135369 Nov 2010 WO
WO 2011020633 Feb 2011 WO
WO 2012071476 May 2012 WO
WO 2013040079 Mar 2013 WO
WO 2013148275 Oct 2013 WO
WO 2014150292 Sep 2014 WO
WO 2014151070 Sep 2014 WO
WO 2014164569 Oct 2014 WO
WO 2015073571 May 2015 WO
WO 2015184173 Dec 2015 WO
WO 2016154066 Sep 2016 WO
WO 2016187355 Nov 2016 WO
WO 2017015633 Jan 2017 WO
WO 2017030917 Feb 2017 WO
WO 2017040853 Mar 2017 WO
WO 2017040855 Mar 2017 WO
WO 2017053885 Mar 2017 WO
WO 2017087713 May 2017 WO
WO 2017184881 Oct 2017 WO
WO 2019036025 Feb 2019 WO
WO 2019070385 Apr 2019 WO
WO 2020172615 Aug 2020 WO
Non-Patent Literature Citations (47)
Entry
Alexander, L., et al., Disistronic Polioviruses as Expression Vectors for Foreign Genes. 1994. Aids Research and Human Retroviruses. vol. 10, Supplement 2, S57-S60.
Bae, et al., “In vitro experiment of the pressure regulating valve for a glaucoma implant”, Journal of Micromechanics and Microengineering 13.5, 13:613-619, No. 5, Sep. 2003.
Bucciarelli, Patrice D., Working Model is Next Step in Team's Long Journey to Commercial Product, Healthfirst, Business First of Louisville, louisville.bizjournals.com, Feb. 27, 2004.
Cairns, J.E., “Trabeculectomy: Preliminary report of a new method”, Am. J. Ophthalmology, 66:673-79 (1968).
“Changing Perspectives in Glaucoma Management,” Innovations in Glaucoma 2010.
Chen, et al., “Trabeculetomy combined with implantation of sil-icon rubber slice for intractable glaucoma”, Eye Science, 18:95-98, vol. 2, Jun. 2002.
Fine, Ben S., et al., “A Clinicopathologic Study of Four Cases of Primary Open-Angle Glaucoma Compared to Normal Eyes”, American Journal of Ophthalmology, vol. 91, No. 1, 1981, pp. 88-105.
Fiore, P.M., et al., Use of neodymium: YAG laser to open an occluded molteno tube, Ophthalmic Surgery, May 1989; 20(5): 373-74.
Gimbel, H.V., et al., “Small incision trabeculotomy combined with phacoemulsificatin and intraocular lens implantation”, J Cataract Refract Surg, vol. 19:92-96 (Jan. 1993).
Gothwal, et al., “Migration of seton into the anterior chamber”, Eye, 16:85-97, 2002.
Hoskins, H. Dunbar, et al., “Diagnosis and Therapy of the Glaucomas”, Chapter 4: Aqueous Humor Outflow, 61 Edition, pp. 41-66 (1989) (28 pages).
Huang, Morgan C., et al., “Intermediate-term Clinical Experience with the Ahmed Glaucoma Valve Implant”, 127 Am. J. Ophthalmol. 27 (Jan. 1999).
Johnson, et al., “Schlemm's Canal Becomes Smaller After Successful Filtration Surgery”, (reprinted) ARCM Ophthalmol—vol. 118, Sep. 2000 (www.archophthalmol.com) p. 1251-1256.
Jordan, et al., “A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma,” J Glaucoma 15(3): 200-205 (2006).
Kampik, Anselm Franz Grehn, “Nutzen und Risiken Augenärzticher Therapie”, Hauptreferate der XXXIII, Essener Fortbildung für Augenärzte, Dec. 1998. (English translated version enclosed Benefits and Risks of Ophthalmological Therapy).
Kershner, Robert, “Nonpenetrating trabulectomy with placement of a collagen drainage device”, J. Cataract Refract. Sug., 21:608-611 (1995).
Klemm, A. Balazs, J. Draeger, R. Wiezorrek, “Experimental use of space-retaining substances with extended duration: functional and morphological results”, Graefe's Arch Clin Exp Ophthalmol (1995) 233:592-597.
Krupin, Theodore, et al., “Filtering valve implant surgery for eyes with neovascular glaucoma”, 89 Am. J. Ophthalmol. 338 (Mar. 1980).
Mermoud, A., et al., “Comparison of deep sclerectomy with collagen implant and trabeculectomy in open-angle glaucoma”, J. Cataracat Refract. Surg., vol. 25, No. 3, Mar. 1999, pp. 323-331 (abstract only).
Miyazaki, Akiko, et al., “Postoperative Results of Combined Trabeculotomy, Phacoemuisification and Intraocular Lens Implantation With Self-Sealing Wound”, Japanese Journal of Ophthalmic Surgery, 1997, pp. 537-542, vol. 10, No. 4.
Molteno, A.C.B., et al., “Implants for draining neovascular glaucoma”, 61 Br. J. Ophthalmol. 120 (1977).
Moses, Robert A., M.D.; “Circumferential Flow in Schlemm's Canal”, American Journal of Ophthalmology, Sep. 1979, vol. 88, No. 3, Part II, :pp. 585-591.
Nguyen, Quang H., et al., “Complications of Baerveldt Glaucoma Drainage Implants”, 116 Arch. Ophthalmol. 571 (May 1998).
Refojo, “Current status of biomaterials in ophthalmology”, Survey of ophthalmology, 26:257-265, No. 5, 1982.
Rizq, et al., “Intraocular Pressure Measurement at the Choroid Surface: A Feasibility Study with Implications for Implantable Microsystems”, Br J Ophthalmol 2001; 85:868-871, Jul. 2001.
Saxena, Sandeep. “Clinical Ophthalmology”. 2011. pp. 245.
Schocket, “Investigations of the Reasons for Success and Failure in the Anterior Shunt-to-the Encircling-Band Procedure in the Treatment of Refractory Glaucoma”, Tr. Am. Ophth. Soc., 84:743 (1986).
Scott, et al., “Use of glaucoma drainage devices in the management of glaucoma associated with aniridia”, American Journal of Ophthalmology, 135:155-159, No. 2, Feb. 1, 2003.
Shields, M. Bruce, MD, “A Study Guide for Glaucoma: Aqueous Humor Dynamics”, Copyright 1982, pp. 6-43.
Spiegel, Detlev, “Benefits and Risks of Ophthalmological Treatment” Bucherei des Augenarztes I the Ophthalmologist's Library, vol. 139, Oct. 15, 1998.
Stefansson, J., “An Operation for Glaucoma”, American J. Ophthalmology, 8:681-693 (1925).
Tham, et al., “Incisional surgery for angle closure glaucoma”, Seminars in Ophthalmology, 17:92-99, No. 2, Jun. 2002.
Topouzis, Fotis, et al., “Follow-up of the Original Cohort With the Ahmed Glaucoma Valve Implant”, 128 Am. J. Ophthalmol. 198 (Aug. 1999).
“Transcend Medical CyPass® System—Instructions for Use,” (Release date Apr. 29, 2013).
Tripathi, et al., “Functional Anatomy of the Anterior Chamber Angle”, Biomedical Foundation of Ophthalmology, vol. 1, Chapter 10,pp. 1-74; edited by Thomas Dune and Edward Jaeger, Revised Edition, 1983,—Harper & Row, Publishers.
Tun, et al.,“Assessment of Trabecular Meshwork Width Using Swept Source Optical Coherence Tomography”, 251:6 Graefes Arch. Clin. Exp. Ophthalmol. 1587 (2013).
Wagner, et al., “Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused Under Constant Pressure”, Invest Ophthalmol Vis Sci. Sep. 2004; 45(9): 3203-3206 (9 pages).
Webster's Third New International Dictionary of the English Language (Unabridged), definitions of “deploy” and “deployment”, p. 605 (2002) (4 pages).
Wilcox, Michael J. et al. “Hypothesis for Improving Accessory Filtration by Using Geometry”, J. Glaucoma, vol. 3, No. 3, pp. 244-247 (1994).
Wilcox et al., Latest Research: Tear Biomarkers, Jun. 29, 2011, 5 pages.
Wilcox, Michael J. et al. “Performance of a New, Low-volume, High-Surface Area Aqueous Shunt in Normal Rabbit Eyes”, J. Glaucoma, vol. 9, No. 1, pp. 74-82 (Feb. 2000).
Wilson, Ellen D., “Implants offer choices for glaucoma surgeons”, EW Glaucoma, Oct. 11, 1999, website “http:--www.eyeorld.org-sep99-999p60.asp”.
Yan, et al., “Schlemm's Canal and Trabecular Meshworkin Eyes with Primary Open Angle Glaucoma: A Comparative Study Using High-Frequency”, PLOS ONE, 15 pages, Jan. 4, 2016.
European Exam Report, EPO App. No. 08 102 896.1, dated Nov. 4, 2010.
Communication from European Patent Office for European App. No. 08102896.1 (dated Jul. 2, 2012) (5 pages).
Appeal in European Application No. 08102896.1 dated Aug. 27, 2012.
International Search Report and Written Opinion in PCT/US2016/053570 dated Mar. 9, 2017.
Related Publications (1)
Number Date Country
20190091012 A1 Mar 2019 US
Provisional Applications (1)
Number Date Country
62564972 Sep 2017 US